摘要
目的观察培美曲塞联合奥沙利铂治疗进展期肺腺癌的疗效及毒副反应。方法 51例经病理及组织细胞学证实为肺腺癌患者,既往一线化疗失败,接受培美曲塞联合奥沙利铂方案治疗,每例患者至少完成2周期。结果 51例患者中,CR 0例,PR 6例,SD 32例,PD 13例,有效率为11.76%(6/51),疾病控制率为74.51%(38/51)。主要毒副反应为骨髓抑制、消化道反应、神经毒性。结论培美曲塞联合奥沙利铂治疗进展期肺腺癌疗效较好,毒副反应可耐受。
Objective To observe the efficacy and toxicities of pemetrexed plus oxaliplatin in the treatment of advanced pulmonary adenocarcinoma. Methods Fifty-one patients with pulmonary adenocarcinoma failed to the first line chemotherapy accept pemetrexed plus oxaliplatin treatment, each patients completed at least two cycles. Re- suits Of the 51 patients, no CR was observed, PR was observed in the 5 patients, SD in the 33 patients, PD in the 13 patients,the response rate was 11.76% （6/51） ,the disease control rate was 74.51% （38/51）. The main toxicities were marrow suppression,gastrointestinal reaction and neurotoxicity. Conclusion Pemetrexed plus oxaliplatin is effective for advanced pulmonary adenocarcinoma, and the toxicities can be tolerated.
出处
《肿瘤基础与临床》
2013年第2期114-116,共3页
journal of basic and clinical oncology
关键词
肺腺癌
培美曲塞
奥沙利铂
pulmonary adenocarcinoma
pemetrexed
oxaliplatin
